{"filing":{"accession_number":"0001193125-26-274291","cik":"0001882782","ticker":"ODTX","company_name":"Odyssey Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"odtx-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-20260617.htm"},"events":[{"id":11615,"run_id":10202,"accession_number":"0001193125-26-274291","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8257,"accession_number":"0001193125-26-274291","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:46:14.541887+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8257,"accession_number":"0001193125-26-274291","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:46:14.541887+00:00","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-06-17"}]}